CLDT vs FRPH

CLDT presents a conflicted profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $8.61 exceeds both the Graham Number ($6.99) and the Intrinsic Value ($0.98). While the company maintains a healthy Debt/Equity ratio (0.46) and trades at a deep discount to book value (P/B 0.55), these strengths are offset by a critical dividend payout ratio of 257.14% and declining year-over-year revenue (-9.90%). The stock is currently trading at a premium to its defensive fair value, supported more by recent price momentum and analyst optimism than by fundamental earnings growth.

FRPH exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9 and an exceptional current ratio of 14.77, indicating a fortress balance sheet. However, this financial stability is decoupled from its valuation; the stock trades at a massive premium to its Graham Number ($11.22) and Intrinsic Value ($1.75), with a P/E ratio of 90.88. Severe earnings contraction (-57.10% YoY) combined with bearish insider selling and a negative long-term price trend suggests the current valuation is unsustainable.